Ingenuity and Agilent to Offer Interoperability in Bioinformatics Software
News May 02, 2006
Genomics researchers will be able to exchange data between both applications, leveraging each system's ability to analyze high-volume gene expression data and to perform advanced biological pathway analysis.
"GeneSpring is designed to answer biological questions at the intersection of genomics, genetics, proteomics and biomarker screening," said Jordan Stockton, Agilent Informatics marketing manager.
"The integration with Ingenuity Pathways Analysis also supports our mutual customers by providing rigorous statistical analysis, followed immediately by a comprehensive exploration of relevant biological pathways. Ultimately, our users can address a more complete range of research questions."
"By integrating the Ingenuity Pathway Analysis solution with GeneSpring, our joint customers will have greater flexibility and bandwidth for analyzing and accessing their gene expression data," said Tuan Nguyen, VP, Partner and Professional Services of Ingenuity Systems.
"This collaboration is part of our strategy to seamlessly integrate Ingenuity Pathways Analysis into the natural workflow of our customers, allowing them to uncover mechanisms of action, predict potential toxicities and give biological meaning to their gene expression data with internal or third-party tools."
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.